Papers
12
Total Citations
155
H-Index
8
About
Marco Racioppi is a leading urologic surgeon and researcher at the forefront of robotic-assisted surgery, with a primary focus on prostate and bladder cancer. His major contributions center on the rigorous evaluation of novel surgical platforms, most notably the Hugo™ RAS system, through pioneering comparative studies against the established daVinci platform. His work has demonstrated the safety, efficacy, and non-inferiority of these emerging technologies, with key papers on robot-assisted radical prostatectomy (RARP) and radical cystectomy (RARC) garnering over 20 citations each. Racioppi has also advanced surgical quality metrics by assessing "Trifecta" and "Pentafecta" outcomes, and his multi-surgeon learning curve analysis for positive surgical margins has direct implications for surgical training. Beyond technical innovation, he has addressed critical healthcare topics, including the impact of the COVID-19 pandemic on urology residency and the cost-efficacy of robotic technology in the Italian healthcare system. With a growing body of highly cited work, Racioppi is shaping the future of minimally invasive urologic oncology.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4How Can the COVID-19 Pandemic Lead to Positive Changes in Urology Residency?22 citations · 2020
- 5
- 6
- 7
- 8
- 9
- 10